<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1426992C-4C2A-4FDE-8957-DA5511E95031"><gtr:id>1426992C-4C2A-4FDE-8957-DA5511E95031</gtr:id><gtr:name>Entasis Therapeutics</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:department>School of Life Sciences</gtr:department><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1426992C-4C2A-4FDE-8957-DA5511E95031"><gtr:id>1426992C-4C2A-4FDE-8957-DA5511E95031</gtr:id><gtr:name>Entasis Therapeutics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CF11C8EB-DE92-4FC8-8F5D-477390597C44"><gtr:id>CF11C8EB-DE92-4FC8-8F5D-477390597C44</gtr:id><gtr:name>McMaster University</gtr:name><gtr:address><gtr:line1>1280 Main Street West</gtr:line1><gtr:line4>Hamilton, Ontario</gtr:line4><gtr:line5>L8S 4L8</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/11C45689-C208-49DC-A95B-1B971827AEB3"><gtr:id>11C45689-C208-49DC-A95B-1B971827AEB3</gtr:id><gtr:name>Merck &amp; Co Inc</gtr:name><gtr:address><gtr:line1>Merck &amp; Co Inc</gtr:line1><gtr:line2>One Merck Drive</gtr:line2><gtr:line4>Whitehouse Station</gtr:line4><gtr:line5>NJ 08889-0100</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D6C3234E-5048-4AA0-A116-0CAC51569B2D"><gtr:id>D6C3234E-5048-4AA0-A116-0CAC51569B2D</gtr:id><gtr:name>University of Queensland</gtr:name><gtr:address><gtr:line1>University of Queensland</gtr:line1><gtr:line4>Brisbane</gtr:line4><gtr:line5>Queensland 4972</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F327D9BD-7240-42B0-85D7-28BE87B9576C"><gtr:id>F327D9BD-7240-42B0-85D7-28BE87B9576C</gtr:id><gtr:name>Novartis Pharma AG</gtr:name><gtr:address><gtr:line1>WKL - 136.5.22</gtr:line1><gtr:line4>Basel</gtr:line4><gtr:line5>CH 4002</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/DC3E968D-06C2-4F03-9987-D58301F99BC6"><gtr:id>DC3E968D-06C2-4F03-9987-D58301F99BC6</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:otherNames>Gerrard</gtr:otherNames><gtr:surname>Dowson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FN00390X%2F1"><gtr:id>9B8851D1-5FF6-465A-A24E-1586BF425907</gtr:id><gtr:title>International exploitation of new reagents and assays for antibiotic discovery</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/N00390X/1</gtr:grantReference><gtr:abstractText>USA</gtr:abstractText><gtr:fund><gtr:end>2016-07-19</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2015-07-20</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>5400</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Entasis Therapeutics</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Entasis collaboration</gtr:description><gtr:id>9CD32322-F5DD-44E4-835D-DDE4F5089084</gtr:id><gtr:impact>Successful award of Wellcome Trust Pathfinder award</gtr:impact><gtr:outcomeId>56d7119fa7b0d7.56139738-1</gtr:outcomeId><gtr:partnerContribution>Assay validation and hit characterisation insight</gtr:partnerContribution><gtr:piContribution>Biochemistry and assay development</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Radio 4 3 part drama production</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F4D27A65-3C0E-49C5-9BC6-9AD95699FCAE</gtr:id><gtr:impact>Radio drama highlighting factors driving antibiotic resistance and global consequences - raising public awareness at the National level</gtr:impact><gtr:outcomeId>58c046375243a6.38169246</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/programmes/b08g7y1l</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>O'Neil AMR review</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>721C6963-EB37-4010-B5F6-A08C194A147B</gtr:id><gtr:impact>In December we published our first report1
 showing that infections caused by
drug-resistant pathogens are one of the biggest health problems the world faces
today. Bacteria and other pathogens have always evolved to resist the new drugs
that modern medicine uses to combat them. But in recent years the rise in drug
resistance has been a particular worry, especially the emergence of antibioticresistant
superbugs. Unless action is taken to address this huge global issue, our
conservative estimate is that it will cost the world an additional 10 million lives
a year by 2050, more than the number of people currently dying from cancer
annually. It will also have a cumulative cost of 100 trillion USD, more than one
and a half times annual world GDP today, or roughly the equivalent to losing the
UK economy from global output every year.
We now turn our attention to how this problem can be tackled. This paper is the
first in a series that works towards global and sustainable solutions. There are
many angles to the problem that we will need more time to consider. In particular,
the focus of our next paper, due to be published in the spring, will be how to
stimulate the market for companies to invest in and develop new antimicrobials and
diagnostics, which is not fully addressed here. There we will assess potential 'push'
and 'pull' incentives to encourage the development of new antimicrobial drugs,
and set out our proposals for action by policy makers. In later papers we will also
focus on important issues such as the use of antibiotics in agriculture and potential
alternatives to antimicrobials</gtr:impact><gtr:outcomeId>58c029099c4fc0.57853073</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:url>https://amr-review.org/sites/default/files/Report-52.15.pdf</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>United Nations General Assembley</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F3E02D79-D04E-486F-88B3-4B031D4552D1</gtr:id><gtr:impact>Invited to attended AMR working group presentations</gtr:impact><gtr:outcomeId>58c0273593b0c4.63166506</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:url>http://www.un.org/pga/71/event-latest/high-level-meeting-on-antimicrobial-resistance/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pew Road Map for Antibiotic Discovery</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6E08C8F4-C0AB-4FA3-99B0-75A1293EF1A4</gtr:id><gtr:impact>The Pew Charitable Trusts convened a multidisciplinary group of leading industry and academic experts to
identify the key scientific roadblocks to antibiotic discovery and consulted with numerous other public and
private sector stakeholders to develop a Scientific Roadmap for Antibiotic Discovery. The roadmap outlines a
concrete approach-both a scientific plan and organizational structure to support this research-that would lay a
foundation for the sustained and diversified discovery and development of new antibiotics and therapies over the
coming decades.The report's key findings show a need for:
? A targeted approach to tackle the basic scientific barriers impeding antibiotic discovery and development.
? A better understanding of how to overcome the cellular defenses of drug-resistant Gram-negative bacteria,
which cause some of the most difficult-to-treat infections.
? Generation of new chemical matter designed for antibiotic discovery.
? Tools and methodologies to evaluate promising alternatives to traditional antibiotic use.
? A framework for sharing information, expertise, and materials across the research community to foster
innovative science and spur the discovery of novel antibacterial therapies.</gtr:impact><gtr:outcomeId>58c02852e99b88.25933695</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:url>http://www.pewtrusts.org/~/media/assets/2016/05/ascientificroadmapforantibioticdiscovery.pdf</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ANTRUK Antibiotic Research UK</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6415122C-8093-4055-A2D2-D92E9723145C</gtr:id><gtr:impact>Establishment of new charity and new fundraising campaign

regional and national media interest</gtr:impact><gtr:outcomeId>546379ce7d5364.35735848</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.antibioticresearch.org.uk</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>3200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC AMR theme 1 collaboration award</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>7B1C276D-8F69-4291-A85C-F4C4D10B67DA</gtr:id><gtr:outcomeId>56d8157090be48.91336228</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Accelerate CHNUK AMR discovery: Establishing joint China/UK training and research platforms enabling highthroughput fragment based inhibitor discovery</gtr:description><gtr:end>2019-05-02</gtr:end><gtr:fundingOrg>Newton Fund</gtr:fundingOrg><gtr:fundingRef>MR/P007503/1	</gtr:fundingRef><gtr:id>699F3AA0-FA51-4D35-ABED-355F43677EEB</gtr:id><gtr:outcomeId>58c01eb404f7b0.11079733</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>Enabled further international engagement with industry, defence agencies and government</gtr:description><gtr:firstYearOfImpact>2015</gtr:firstYearOfImpact><gtr:id>0A33939E-477E-4114-8D53-24132F2CE47F</gtr:id><gtr:impactTypes><gtr:impactType>Economic,Policy &amp; public services</gtr:impactType></gtr:impactTypes><gtr:outcomeId>56d70ec2253251.47919754</gtr:outcomeId><gtr:sector>Aerospace, Defence and Marine,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology,Security and Diplomacy</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>Lobbying policy makers and funders to support multidisciplinary research in support of AMR discovery</gtr:description><gtr:exploitationPathways>Future strategy for AMR development and funding</gtr:exploitationPathways><gtr:id>C56F8D92-FAA4-4B3D-85AD-5F62FA8BBE4E</gtr:id><gtr:outcomeId>56d70f21c79500.33667286</gtr:outcomeId><gtr:sectors><gtr:sector>Aerospace, Defence and Marine,Government, Democracy and Justice,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Antimicrobial Discovery Solutions Ltd</gtr:companyName><gtr:description>Reagents, assay development and services</gtr:description><gtr:id>AD4EF739-3E0B-4819-B5C3-2C9C69682CC9</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>56d71729c98853.70466576</gtr:outcomeId><gtr:yearCompanyFormed>2015</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>DEDC7EC0-8C7A-46E5-B430-5E1BCF3B3ED2</gtr:id><gtr:title>Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis.</gtr:title><gtr:parentPublicationTitle>European journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/570dcdda9f8064c09def9cbe6583ab32"><gtr:id>570dcdda9f8064c09def9cbe6583ab32</gtr:id><gtr:otherNames>Vajs J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0223-5234</gtr:issn><gtr:outcomeId>58c021836a82b7.98179248</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13635B84-291E-4F12-9123-D864748A4523</gtr:id><gtr:title>Sansanmycin natural product analogues as potent and selective anti-mycobacterials that inhibit lipid I biosynthesis.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e93a23805972b417db19d67fd4fe977"><gtr:id>4e93a23805972b417db19d67fd4fe977</gtr:id><gtr:otherNames>Tran AT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58c020f563c651.74250403</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/N00390X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>